Company Overview and News
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX:CEU) (OTC:CESDF) is pleased to announce the results of the matters to be voted on at the annual general meeting of shareholders held on June 14, 2018 (the “Meeting”). Based on the proxies received and on a ballot conducted at the Meeting, the following individuals, being the eight nominees listed in the management information circular of the Corporation dated May 1, 2018 (the “Circular”), were elected as directors of the Corporation until the next annual shareholders’ meeting:
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. (“CES” or the “Corporation”) (TSX:CEU) (OTC:CESDF) is pleased to announce its intent to implement a normal course issuer bid (“NCIB”) and the approval by the Board of Directors of the Corporation to double its monthly cash dividend to $0.005 per common share. The increased cash dividend of $0.005 per common share will be paid on July 13, 2018 to the shareholders of record at the close of business on June 29, 2018.
CALGARY, Alberta, May 10, 2018 (GLOBE NEWSWIRE) -- CES Energy Solutions Corp. ("CES" or the “Company”) (TSX:CEU) (OTC – Nasdaq Intl:CESDF) is pleased to report on its financial and operating results for the three months ended March 31, 2018. Further, CES announced today that it will pay a cash dividend of $0.0025 per common share on June 15, 2018 to the shareholders of record at the close of business on May 31, 2018.
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced the conclusion of its 3rd Nasdaq International Designation Virtual Investor Conference on April 4, 2018. Nasdaq welcomed select Nasdaq International Designation Member Companies to present their current state of business to a broad audience including potential investors. The Conference also provided individual and institutional investors an opportunity to engage with CEOs, CFOs, and IROs from a wide range of sectors globally.
AJX CEU NMT NHVCF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:CEU / Canadian Energy Svcs and on message board site Silicon Investor.